NMD Pharma
PrivateLast Round
Series B
Nov 15, 2023
Total Funding Raised
$170.17M
Company Overview
NMD Pharma operates in Healthcare & Life Sciences and is based in Aarhus. Its latest recorded funding round was a Series B round in November 2023.
NMD Pharma is a biotechnology company that develops a first-in-class platform of small molecule therapies for the treatment of severe neuromuscular disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NMD Pharma Comparables
Compare NMD Pharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Augustine Therapeutics | 77% | |
| Setara Biosciences | 77% | |
| Edgewise Therapeutics | 74% |
For institutional investors. Book with your work email.
NMD Pharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Nov 15, 2023 | ||||
| Series A Extension | Feb 15, 2022 | ||||
| Series A | Mar 23, 2018 | ||||
| Seed | Jun 1, 2016 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
NMD Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Lundbeck Foundation | Series A Extension |
| Roche Venture Fund | Series B, Series A, Series A Extension |
| Lundbeckfonden BioCapital | Series B |
| Roche Venture Fund | Series B, Series A, Series A Extension |
| Novo Holdings | Grant, Series B, Seed, Series A, Series A Extension |
| Inkef Capital | Series B, Series A Extension, Series A |
| Capnova | Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 10, 2026
Presented SYNAPSE-CMT study data at the MDA Conference.
- Mar 10, 2026
Top-line safety and efficacy data released for ignaseclant in Phase 2a study.
For institutional investors. Book with your work email.
NMD Pharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about NMD Pharma's valuation, stock price, and market status.
Is NMD Pharma a public or private company?
NMD Pharma is a private company.
What is the current stock price of NMD Pharma?
NMD Pharma is a private company, so its shares have no public market price. Caplight tracks NMD Pharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is NMD Pharma worth (valuation)?
Valuation information for NMD Pharma is not publicly available.
Can I buy NMD Pharma stock?
NMD Pharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was NMD Pharma's last funding round?
NMD Pharma's most recent funding round was Series B on November 15, 2023.
Who are the main investors in NMD Pharma?
Key investors in NMD Pharma include Inkef Capital, Jeito Capital.
Will NMD Pharma IPO soon?
No public IPO plans have been announced for NMD Pharma.
How can I track NMD Pharma secondary market activity?
Caplight tracks bids, offers, and trades in NMD Pharma's shares on secondary markets.